论文部分内容阅读
目的：探讨基因重组人红细胞生成素（ｒｈＥｐｏ）对非肾性贫血的治疗作用。方法：用ｒｈＥｐｏ对２９例非肾性贫血进行治疗，其中包括再生障碍性贫血（ＡＡ）６例，骨髓增生异常综合征（ＭＤＳ）１２例，多发性骨髓瘤（ＭＭ）５例，非霍奇金淋巴瘤（ＮＨＬ）６例，疗程３个月，观察其疗效及毒副作用。结果：１８例治疗后Ｈｂ有不同程度上升，总有效率为６２．０％。各组有效率分别为：ＡＡ组６６．６％（４／６）；ＭＤＳ组５８．３％（７／１２），其中难治性贫血（ＲＡ）为８５．７％（６／７），转变中的原始细胞增多型（ＲＡＥＢｔ）２例均无效；ＭＭ组８０．０％（４／５）；ＮＨＬ组５０．０％（３／６）。结论：ｒｈＥｐｏ可使非肾性贫血获得不同程度改善，ＭＤＳ组中ＲＡ及ＭＭ患者疗效较显著。ｒｈＥｐｏ不良反应小，使用安全。
Objective: To investigate the therapeutic effect of recombinant human erythropoietin (rhEpo) on non-renal anemia. Methods: Twenty-nine patients with non-renal anemia were treated with rhEpo, including 6 with aplastic anemia (AA), 12 with myelodysplastic syndrome (MDS), 5 with multiple myeloma (MM) Gold lymphoma (NHL) in 6 cases, the course of 3 months to observe the efficacy and side effects. Results: After treatment, Hb increased to some extent with a total effective rate of 62.0%. The effective rates in each group were 66.6% (4/6) in AA group and 58.3% (7/12) in MDS group, of which the refractory anemia (RA) was 85.7% (6/7) In the transitional RAEB-t, 2 cases were ineffective; 80.0% (4/5) in MM group and 50.0% (3/6) in NHL group. Conclusion: rhEpo can improve non-renal anemia to some extent, and the effect of MDS group is better than that of RA and MM. Adverse reactions of rhEpo small, safe to use.